

ANZHNCS ASM 2019

Australian and New Zealand Head & Neck Cancer Society
21st Annual Scientific Meeting

19 – 21 September 2019
Adelaide Convention Centre

ADELAIDE, SOUTH AUSTRALIA

New Science, Better Treatments



© Peter Clarke Photography



© National Wine Centre of Australia



AUSTRALIAN AND NEW ZEALAND
HEAD & NECK
CANCER SOCIETY

www.anzhnccs.org

Platinum Sponsor:



Bristol-Myers Squibb



Registration
Brochure

© Hirokazu Ishino

Letter of Invitation

On behalf of the organising committee, it is my pleasure to invite you to join us for the ANZHNCS Annual Scientific Meeting from Thursday 19 September to Saturday 21 September 2019 in Adelaide, South Australia. The meeting theme is 'New Science, Better Treatments' and we look forward to exploring this theme throughout the program.

We are pleased to announce the participation of the following keynote speakers who will bring their expertise and knowledge to share with our delegates. Dr David Fuller from The University of Texas MD Anderson Cancer Center, Texas, USA, Dr Timothy McCulloch from University of Wisconsin School of Medicine and Public Health, Wisconsin, USA, Dr Cherith Semple from Ulster University and Southern Eastern Health and Social Care Trust, Belfast, Northern Ireland and Dr Raymond King-Yin Tsang from The University of Hong Kong, Hong Kong.

We would like to take this opportunity to acknowledge and thank our major sponsors in particular our platinum sponsor, Bristol-Myers Squibb and bronze, sponsors Device Technologies and KLS Martin Australia. We would also like to thank all the companies participating in the industry exhibition. Your continued support is greatly valued.

Delegates are encouraged to submit one or more abstracts for consideration on the program. Opportunities will be available for oral presentations and posters. Please refer to the Call for Abstracts section of this brochure for submission information.

We look forward to welcoming you to the meeting in September.

Yours sincerely,



Dr Brian Stein

Medical Oncologist,
Adelaide Cancer Centre/Royal Adelaide Hospital, Adelaide
Convener, ANZHNCS ASM 2019



2019 Organising Committee

Convener

Brian Stein - Medical Oncologist, Adelaide Cancer Centre/Royal Adelaide Hospital

Committee Members

Peter Gorayski - Radiation Oncologist, Royal Adelaide Hospital

Andrew Foreman, FRACS - ENT/Head and Neck Surgeon, Royal Adelaide Hospital

Mistyka Schar - Speech Pathologist, Flinders Medical Centre

Emma-Louise Vale - Dietitian, Flinders Medical Centre

Alison Richards - Speech Pathologist, Royal Adelaide Hospital

Caroline Whiteford - Head and Neck Cancer Nurse Consultant, Royal Adelaide Hospital

Australian and New Zealand Head & Neck Cancer Society (ANZHNCS)

Early in 1998, a number of head and neck oncologists from the disciplines of surgery, radiation oncology and medical oncology met in Sydney to discuss the feasibility of establishing a multidisciplinary head and neck cancer society. A working party was formed and following a number of meetings, invitations were sent to individuals in these three specialties to become foundation members of the Australian and New Zealand Head & Neck Cancer Society.

The initial business meeting was held on December 9, 1998 and at that time there were 60 foundation members. The Society adopted as its Constitution the Model Rules for Associations published by the Department of Fair Trading in NSW and the members agreed that their principal objectives would be to promote the practice of head and neck oncology, to educate medical colleagues and the public about our specialty, to foster research and to seek optimal treatment outcomes for our patients.

Who should attend?

The meeting is designed for health professionals working in the area of head and neck oncology including; ENT surgeons, plastic and reconstructive surgeons, head and neck surgeons, oral and maxillofacial surgeons, medical oncologists, surgical oncologists including endocrine surgeons, radiation oncologists, registrars, speech pathologists, nurses, dietitians, psychologists, medical students and other health professionals.

Sponsors and Exhibitors *(as at time of publication)*

Sponsors

Platinum Sponsor:



Bristol-Myers Squibb

Bronze Sponsors:



Medtronic

Educational Grant Sponsor:



Exhibitors

AMSL

Atos Medical

Australian and New Zealand
Head & Neck Cancer Society

Beyond Five

Boehringer Ingelheim

Bristol-Myers Squibb

Device Technologies

Flavour Creations

GenesisCare

Icon Cancer Centre

KLS Martin Australia

Medtronic Australasia Pty Ltd

Menarini Australia Pty Ltd


MSD

ZEISS



OPDIVO almost tripled the overall survival rate at 2 years vs investigator's choice in previously treated R/M SCCN^{1*}

**p-value for 2-year overall survival vs investigator's choice not reported.¹*



Median overall survival 7.7 months (95% CI 5.7–8.8) with OPDIVO vs 5.1 months (95% CI 4.0–6.2) with investigator's choice; HR 0.68, 95% CI 0.54–0.86 (p-value not reported for the updated analysis).¹

Adapted from Ferris RL *et al.*, 2018.¹

CheckMate 141: Phase 3, randomised, open-label study of patients (n=361) with squamous cell carcinoma of the oral cavity, pharynx or larynx and tumour progression or recurrence within 6 months of the last dose of platinum-based therapy. Primary outcome was overall survival. Investigator's choice of either methotrexate (n=52), docetaxel (n=54) or cetuximab (n=15). Minimum follow-up for the updated analysis was 24.2 months.¹ NOTE: In the initial analysis of CheckMate 141 (median duration of follow-up 5.1 months), the median overall survival was 7.5 months (95% CI 5.5–9.1) with OPDIVO vs 5.1 months (95% CI 4.0–6.0) with investigator's choice; HR 0.70, 97.73% CI 0.51 to 0.96, p = 0.01).²

- Fewer discontinuations due to treatment-related adverse events with OPDIVO vs investigator's choice (4% vs 9%, respectively).¹
- OPDIVO is associated with immune-related adverse reactions. **Patients should be monitored continuously** as these reactions may occur at any time during or after discontinuation of therapy.³

OPDIVO SCCHN PBS information⁴



PBS LISTED

PBS listing: Recurrent or metastatic squamous cell carcinoma of the oral cavity, pharynx or larynx^{4†}

PBS criteria for initiation⁴

- Patient must have a WHO performance status of 0 or 1, **AND**
- The treatment must be the sole PBS-subsidised therapy for this condition, **AND**
- The condition must have progressed within 6 months of the last dose of prior platinum-based chemotherapy, **AND**
- Patient must not have received prior treatment with a PD-1 inhibitor for this condition.

[†]Visit www.pbs.gov.au for full PBS criteria. OPDIVO is TGA-indicated for patients with recurrent or metastatic SCCHN progressing on or after platinum-based therapy.^{3,4}

PBS INFORMATION: OPDIVO monotherapy – Authority required (STREAMLINED) for recurrent or metastatic squamous cell carcinoma of the head and neck (oral, pharynx or larynx). Refer to PBS schedule for full authority information.

Please refer to the Approved Product Information before prescribing. The Product Information is available upon request from BMS Medical Information Department: 1800 067 567 or can be accessed at <http://www.medicines.org.au/files/bqpopdiv.pdf>

WARNING: IMMUNE-RELATED ADVERSE REACTIONS WITH OPDIVO AND YERVOY (IPILIMUMAB) COMBINATION THERAPY

Immune-related adverse reactions are seen more frequently, and are more severe, with OPDIVO and YERVOY combination therapy than with OPDIVO or YERVOY monotherapy. Immune-related adverse reactions can involve any organ system. The majority of these initially manifest during treatment; however, a minority can occur weeks to months after discontinuation. Some immune-related adverse reactions can be permanent (such as thyroid dysfunction and diabetes mellitus). Life-threatening or fatal immune-related adverse reactions that have occurred include colitis, intestinal perforation, hepatitis, pneumonitis, hypophysitis, adrenal insufficiency, toxic epidermal necrolysis, myocarditis, encephalitis and myasthenia gravis (see Sections 4.4 Special warnings and precautions for use and 4.8 Adverse Effects). Early diagnosis and appropriate management are essential to minimise life-threatening complications (see Section 4.2 Dose and method of administration). Monitoring at least prior to each dose is recommended. Advise patients of the importance of immediately reporting possible symptoms. Physicians should consult the YERVOY product information prior to initiation of OPDIVO in combination with YERVOY. The combination of OPDIVO and YERVOY should be administered and monitored under the supervision of physicians experienced with the use of immunotherapy in the treatment of cancer.

AUSTRALIAN MINIMUM PRODUCT INFORMATION: OPDIVO® (NIVOLUMAB) for Squamous Cell Carcinoma of the Head and Neck (SCCHN). For all other indications, please refer to full PI. **NAME OF THE MEDICINE:** OPDIVO® (nivolumab). **INDICATIONS:** OPDIVO as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in patients progressing on or after platinum-based therapy. **DOSAGE AND ADMINISTRATION:** The recommended dose of OPDIVO as a monotherapy administered intravenously over 30 minutes is 3 mg/kg every 2 weeks or 240 mg every 2 weeks or 480 mg every 4 weeks. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient. **CONTRAINDICATIONS:** Hypersensitivity to the active substance or to any of the excipients. **PRECAUTIONS:** OPDIVO as monotherapy and administered in combination with YERVOY is associated with immune-related adverse reactions (irARs) including pneumonitis, colitis, hepatitis, nephritis, renal dysfunction, severe rash or skin reactions (including rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis, some with fatal outcome), endocrinopathies, neurological and other adverse reactions including Vogt-Koyanagi-Harada syndrome and solid organ transplant rejection. Caution in patients with autoimmune disease, immunosuppressive therapy, symptomatic interstitial lung disease, active brain metastases, specific populations excluded from clinical trials, moderate or severe hepatic impairment or severe renal impairment. OPDIVO is not approved for combination with EGFR TKI use in NSCLC. Use in children below 18 years of age is not recommended. Pregnancy Category D. Refer to the Product Information (PI) for a complete list of precautions. **INTERACTIONS WITH OTHER MEDICINES:** OPDIVO is not metabolised by drug metabolising enzymes, therefore it is not expected to have pharmacokinetic-based interactions. **ADVERSE EFFECTS: OPDIVO monotherapy:** Very common (≥10%): fatigue, rash, diarrhoea, nausea, pruritus and neutropenia. Common (≥1/100 to <1/10): upper respiratory tract infection, infusion related reaction, hypersensitivity, hypothyroidism, hyperthyroidism, decreased appetite, peripheral neuropathy, headache, dizziness, hypertension, pneumonitis, dyspnoea, cough, colitis, stomatitis, vomiting, abdominal pain, constipation, dry mouth, vitiligo, dry skin, erythema, alopecia, musculoskeletal pain, arthralgia, pyrexia, oedema (including peripheral oedema) and weight decreased. Please refer to the PI for a full list of adverse events and further details. Prepared from the Approved Product Information dated December 2018.

CI = confidence interval; HR = hazard ratio; PBS = Pharmaceutical Benefits Scheme; PD-1 = programmed cell death protein 1; R/M = recurrent or metastatic; SCCHN = squamous cell carcinoma of the head and neck; WHO = World Health Organization.

References: 1. Ferris RL *et al.* *Oral Oncology* 2018;81:45–51. 2. Ferris RL *et al.* *N Engl J Med* 2016;375:1856–67. 3. OPDIVO® (nivolumab) Approved Product Information (www.medicines.org.au/files/bqpopdiv.pdf). 4. OPDIVO (nivolumab) PBS Information. Available at www.pbs.gov.au Accessed March 2019.

© 2019 Bristol-Myers Squibb. OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company. **BMS Medical Information:** 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322, 4 Nexus Court, Mulgrave, VIC 3170. 1506AU1901822-01. Date of preparation: March 2019. BMSA0978.



Bristol-Myers Squibb



Immuno-Oncology

Keynote Speakers *(correct at time of publication)*



Dr David Fuller

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA

Dr Fuller's research focus remains development of evidence-based "personalised radiotherapy" techniques by incorporation of novel imaging methodologies. To date, the bulk of his work has focused on improving multimodality (e.g. PET-CT, MRI, US) imaging for target delineation in the multi-institutional setting.

He has had specific and singular expertise in imaging physics and human imaging trial design, analysis and execution, acquired as part of his PhD and post-doctoral training. As a formal component of the MD Anderson K12 Paul Calabresi Clinical Trial training program, in addition to direct instruction in clinical trial design and imaging informatics, he has completed ABME board subspecialty certification in Clinical Informatics in addition to primary ABR certification in Radiation Oncology. As a radiation oncologist with informatics certification and formal medical physics training and is uniquely positioned to execute image-guided radiotherapy clinical trials.

His long-term goal is to execute a practice-pattern changing, cooperative group-supported radiotherapy trial which incorporates a quantitative imaging biomarker for risk stratification, adaptive therapy planning, and/or surrogate endpoint use in head and neck cancer.



Dr Timothy M. McCulloch

Professor and Chair of Otolaryngology-Head & Neck Surgery, University of Wisconsin, Wisconsin, USA

Dr McCulloch is a surgical oncologist and laryngologist and is Past-President of the Dysphagia Research Society. He has been an academic surgeon at three major Otolaryngology training programs spanning a career of more than 25 years, with over 150 publications. Dr McCulloch is an active clinician- researcher. His clinical care and research interests are in the areas of laryngeal function, dysphagia, and head and neck cancer and skull base surgery. His work includes basic physiology, surgical innovation and clinical trials. With current collaborative funded research looking to optimise pharyngeal high-resolution manometry in the care of dysphagia patients, and collaborating on an active PCORI funded pragmatic trial addressing the role of eating and exercise while under treatment to prevent long term dysphagia in the head and neck cancer patient.



Dr Cherith Semple

Reader in Clinical Cancer Nursing, Ulster University and South Eastern Health and Social Care Trust, Belfast, Northern Ireland

Dr Semple is an experienced clinical academic with almost twenty years' experience in head and neck cancer nursing and research. She was awarded her PhD in 2006, through the acquisition of a prestigious HSC NI Research & Development Doctoral Fellowship award. Cherith has published widely in academic and professional journals, to include two book chapters.

Her current research interests include, post-treatment quality of life for patients with head and neck cancer and supporting families impacted by parental cancer, which is especially relevant with an increase in younger patients, of a parenting age, being diagnosed with head and neck cancer. This work has included the development of an e-learning module to equip healthcare professionals when communicating with parents newly diagnosed with cancer. Cherith's contribution to cancer nursing has been acknowledged through her award of the RCN NI Nurse of the Year Award in 2015 and her inclusion in the Queen's honour list for MBE in 2017.



The attendance of Dr Tsang has been made possible by an unrestricted educational grant to the ANZHNCS by the SA Foundation of Otorhinolaryngology.



Dr Raymond King-Yin Tsang

Clinical Associate Professor, Department of Surgery, The University of Hong Kong, Hong Kong. Head of the Division of Otorhinolaryngology, Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

Dr Raymond KY Tsang (曾敬賢), MS, MBChB, FRCSEd, FRCSEd(ORL), FHKCORL, FHKAM (Otorhinolaryngology), graduated from the Chinese University of Hong Kong in 1994 and received his training in otolaryngology at the Prince of Wales Hospital, Chinese University of Hong Kong. He obtained his specialist qualification in otolaryngology and fellowship of the Royal College of Surgeons of Edinburgh in 2001 and then sub-specialized in the field of head and neck surgery. He is currently the Associate Professor in the Department of Surgery, University of Hong Kong. He is also the Division Chief of Ear Nose and Throat Surgery of the Department of Surgery, the University of Hong Kong-Shenzhen Hospital in Shenzhen, China.

His clinical research interests include application of robotic surgery in head and neck surgery, minimally invasive surgery in the head and neck region, endoscopic surgery for anterior skull base lesions and swallowing disorders in patients after head and neck cancer treatment. He is actively researching on the application of the next generation flexible robotic surgical system to be used in the head and neck area.

He has published more than 70 peer reviewed papers and book chapters. He is currently the Executive Board Member of the Asian Research Symposium in Rhinology and the International Guild of Robotic and Endoscopic Head and Neck Surgery. He is also the Vice President of the Hong Kong Society of Otorhinolaryngology – Head and Neck Surgery, Chairman of the Head and Neck Subspecialty Board of the Hong Kong College of Otorhinolaryngologists and a member of the Education Committee of the Hong Kong College of Otorhinolaryngologists. He is also the founding council member of the Hong Kong Society of Robotic Surgery.

2019 ANZHNCS Chris O'Brien Orator



Professor Suren Krishnan OAM, FRACS

Professor in the Faculty of Surgery, University of Adelaide, Adelaide, South Australia. Honorary Professor of Deakin University Institute for Intelligent Systems Research, Geelong, Victoria

Suren Krishnan has been a long time friend of Chris O'Brien and his family and considers his time as secretary, when Chris was President of the Australia and New Zealand Head and Neck Society, the highlight of his career.

In July 2008 he became the first surgeon in the southern hemisphere to perform Trans Oral Robotic Surgery at the Royal Adelaide Hospital. He has proctored all Australian Head and Neck Surgeons who have not had the opportunity of robotic fellowships in the USA and has been responsible for the training of the four senior TORS surgeons in the United Kingdom.

Suren has been recognised as Australia's most experienced TORS surgeon. He has been responsible for the introduction of both the INTUITIVE da Vinci robotic surgical platform as well as the MEDROBOTICS Flex system. He has performed or participated in over 400 TORS cases and conducted Australia's first TORS courses. He has participated as an invited speaker at many national and international meetings, as well as, contributing to the international literature on TORS.

He has been recognised with Australia Day and Queen's Birthday honours for his services to head and neck surgery and for voluntary medical services to the Pacific Islands, Indonesia and Africa as well as his service as an active Rotarian.

Provisional Program

Provisional Program correct at the time of publication (April 2019). However, the Meeting Organisers reserve the right to change the program without notice.

We would like to acknowledge the ANZHNCS Foundation for their contribution to funding the below presentations:

Thursday 19 September

Session 2: ANZHNCS Foundation: The Bionic Lid Implant for Natural Eye Closure (BLINC)

Session 3: ANZHNCS Foundation: Adenoid cystic cancer

Session 3: ANZHNCS Foundation: Cancer stem cells in metastatic head and neck cutaneous squamous cell carcinoma

Friday 20 September

Session 7: ANZHNCS Foundation: Can clinical validation of biologic predictors of metastases in head and neck cutaneous squamous cell carcinoma be achieved by transcriptomic profiling

Session 7: ANZHNCS Foundation: Development and validation of new breath analysis tools for noninvasive detection of head and neck cancer

Session 7: ANZHNCS Foundation: Pharyngeal augmentation for dysphagia novel surgical therapy to manage chronic dysphagia post head and neck cancer

Saturday 21 September

Session 9: ANZHNCS Foundation: Magnetic nanotechnology for sentinel lymph node mapping in oral cancer

Thursday 19 September 2019

9:00am – 11:00am Session 1

Meeting Welcome – ANZHNCS Vice President and 2019 ASM Convener
Dr Brian Stein

ANZHNCS Foundation
A/Prof David Wiesenfeld

Chris O'Brien Oration
Professor Suren Krishnan

Keynote Lecture 1

Development and evaluation of a holistic surgical head and neck follow-up clinic using touchscreen technology
Dr Cherith Semple

Keynote Lecture 2

Robots and radiotherapy: the new Science Fiction of HNSCC
Dr Timothy McCulloch

11:00am – 11:30am Morning tea with the industry

11:30am – 1:00pm Session 2

Concurrent Session A – A better way to do it?

ERAS: the surgical perspective
A/Prof Tariq Sammour

Enhanced Recovery After Surgery (ERAS) in head and neck cancer – Where are we now?

Mrs Merran Findlay

ANZHNCS Foundation: The Bionic Lid Implant for Natural Eye Closure (BLINC)

Prof Jonathan Clark

Concurrent Session B – Quality, Risk and the MDT

Dr Raghu Gowda and Dr Andrew Cheng

The development of a Head and Neck Database, a SHNCI experience
Dr Hubert Low

1:00pm – 2:00pm Lunch with the industry

2:00pm – 4:00pm Session 3

Concurrent Session A – Different histologies

ANZHNCS Foundation: Adenoid cystic cancer
Prof Robert Ramsay

ANZHNCS Foundation: Cancer stem cells in metastatic head and neck cutaneous squamous cell carcinoma
Dr Swee T Tan

Free papers

Concurrent Session B – Intervention

RCT results of repetitive dilatation in post CRT patients
ANZHNCS President – A/Prof Julia Maclean

Finding my way: an online psychotherapeutic platform uptake for patients diagnosed with head and neck cancer
Dr Emma Kemp



Laryngectomy and QOL

Dr Jane Bickford

Increasing screening for physical issues and access to early physiotherapy after neck dissection: A translational controlled trial

Dr Aoife McGarvey

Free papers

4:00pm – 4:30pm Afternoon tea with the industry

4:30pm – 6:00pm Session 4 Tumour Board and Poster Warmup

Tumour Board unusual histologies and behaviours

Poster Preview Session: lightning talks

6:00pm – 8:00pm Welcome Reception and Poster Session

Panorama Ballroom
Adelaide Convention Centre

Friday 20 September 2019

9:00am – 11:00am Session 5 – Curing the cured

Keynote Lecture 3

Complications of chemoradiation treatment for nasopharyngeal carcinoma, what an otolaryngologist should know

Dr Raymond King-Yin Tsang

Keynote Lecture 4

Treatment and prevention of dysphagia in head and neck cancer

Dr Timothy McCulloch

Immunotherapy Session

Proudly supported by  Bristol-Myers Squibb

Immunotherapy, cancer and the patient with a transplant

Dr Robert Carroll

Body image

Prof Michael Baigent

Late effects of thyroid and parathyroid loss

Prof David Torpy

11:00am – 11:30am Morning tea with the industry

11:30am – 1:00pm Session 6 – Think it new

Keynote Lecture 5

Artificial intelligence and machine learning in radiotherapy

Dr David Fuller

Keynote Lecture 6

Supporting parents with cancer to communicate their diagnosis to dependent children

Dr Cherith Semple

HPV vaccination

Prof Helen Marshall

Immunotherapy Session

Proudly supported by  Bristol-Myers Squibb

Immuno-radiotherapy

1:00pm – 2:00pm Lunch with the industry

1:00pm – 2:00pm ANZHNCS Annual General Meeting

INTEGRATED SOLUTIONS FOR NECK SURGERY

Recurrent laryngeal nerve (RLN) injury is one of the most serious and underestimated — complications of thyroid surgery.¹⁻⁵

Intraoperative RLN monitoring aids in nerve preservation and is a risk-minimising tool during neck dissections.¹⁻⁵

Ligasure™



NIM Neuro™ 3.0

REFERENCES

1. Lo CY, et al. A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy. *Archives of Surgery* 2000; 135(2):204-7.
2. Randolph GW, et al. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. *Laryngoscope* 2011; 121:S1-S16.
3. Dionigi G, et al. The technique of intraoperative neuromonitoring in thyroid surgery. *Surg Technol Int* 2010; 19:25-37.
4. Dionigi G, et al. Why monitor the recurrent laryngeal nerve in thyroid surgery? *J Endocrinol Invest* 2010; 33:819-22.
5. Randolph GW. Surgery of the thyroid and parathyroid glands. Chapter 25: Surgical anatomy of the recurrent laryngeal nerve. *Elsevier Science (USA)* 2003; 316.

©2018 Medtronic Australasia Pty Ltd. All Rights Reserved.
Medtronic Australasia Pty Ltd. 2 Alma Road Macquarie Park
NSW 2113 PH:1800 668 670 www.medtronic.com.au
UC20181306ANZ 5025-062018

Medtronic

2:00pm – 4:00pm Session 7

Concurrent Session A – Building blocks

Genomics and radiomics in head and neck cancer

Dr David Fuller

ANZHNCS Foundation: Can clinical validation of biologic predictors of metastases in head and neck cutaneous squamous cell carcinoma be achieved by transcriptomic profiling

A/Prof Ruta Gupta

Proton Therapy in Adelaide for 2020

Dr Michael Penniment

ANZHNCS Foundation: Development and validation of new breath analysis tools for non-invasive detection of head and neck cancer

Dr Nuwan Dharmawardana

Free Papers

Concurrent Session B – Quality of life

How do patients cope long-term living with an obturator following maxillectomy? A qualitative study

Dr Cherith Semple

Adjustment and quality of life post HNC treatment

Ms Sarah Wilksch

New approaches to chronic pain

Ms Tiffany Brooks

ANZHNCS Foundation: Pharyngeal augmentation for dysphagia novel surgical therapy to manage chronic dysphagia post head and neck cancer

Ms Mistyka Schar

Free Papers

4:00pm – 4:30pm Afternoon tea with the industry

4:30pm – 6:00pm Session 8

Concurrent Session A – Frailty and the head and neck cancer patient

The impact of computed tomography-defined sarcopenia on outcomes for patients with head and neck cancer

Ms Merran Finlay

Concurrent Session B – How far can you push minimally invasive head and neck surgery

Endoscopic skull base surgery for paranasal sinus cancer

Dr Timothy McCulloch

Robotic and endoscopic nasopharyngectomy

Dr Raymond King-Yin Tsang

7:00pm – 10:30pm Meeting Dinner

Hickinbotham Hall

National Wine Centre of Australia

Saturday 21 September 2019

9:00am – 10:30am Session 9

Concurrent Session A – Multi-Disciplinary Team Discussion

Concurrent Session B – More than just a node

Laser therapy management of lymphoedema post head and neck cancer curative treatment

Ms Sharon Tilley

Microsurgical techniques in the management of lymphoedema

Dr Vani Prasad Atluri

ANZHNCS Foundation: Magnetic nanotechnology for sentinel lymph node mapping in oral cancer

Dr Andrew Foreman

10:30am – 10:45am Morning tea with the industry

10:45am – 12noon Session 10 - Finale

Keynote Lecture 7

Endoscopic Laryngo-Pharyngeal Surgery (ELPS) for resection of early cancers in the hypopharynx and larynx

Dr Raymond King-Yin Tsang

Keynote Lecture 8

Patient selection for Proton therapy head and neck cancer

Dr David Fuller

ANZHNCS Awards

Meeting Close

***ANZHNCS Vice President
and 2019 ASM Convener
Dr Brian Stein***



Call For Abstracts

Abstracts are invited for oral presentations and posters.

Key Dates

Abstract submission deadline:
Monday 17 June 2019

Abstract notification to authors:
Wednesday 10 July 2019

Closure of Early Registration:
Monday 12 August 2019

Abstracts must be submitted via the meeting website.

Submission Guidelines

If there are any difficulties regarding this process please contact the meeting organisers on:
T: +61 3 9249 1158 or E: anzhnscs.asm@surgeons.org

Several points require emphasis:

1. Authors of research papers who wish to have their abstracts considered for inclusion in the program at the ANZHNCS ASM 2019 must submit their abstract electronically via the meeting website adhering to the submission deadline. Abstracts submitted after the closing date will not be considered.
2. Abstract submission is entirely online and paper or facsimile copies will not be accepted. Abstracts will not be submitted by meeting staff on behalf of authors.
3. The title should be brief and explicit.
4. Research papers should follow the format: Purpose, Methodology, Results and Conclusion.
5. Abstracts should not exceed 275 words (excluding the title, author(s) and presenters' name). Any references must be included in this allowance. If you exceed this limit, the excess text will NOT appear in the final program.
6. Include author(s) and indicate presenting author.
7. Include details of main institution.
8. Abbreviations should be used only for common terms. For uncommon terms, the abbreviation should be given in brackets after the first full use of the word.
9. Presentations (slide and video) will only have electronic PowerPoint support. Audio visual instructions will be included in correspondence sent to all successful authors.
10. A 50 word CV is required from each presenter to facilitate their introduction by the session chair.
11. The timing (presentation and discussion) of all papers is at the discretion of the organising committee.
12. Tables, diagrams, graphs, etc CANNOT be accepted in the abstract submission. This is due to the limitations of the computer software program.
13. Please do not type in your abstract onto the submission page. Being internet based, each page on the submission site can only be open for 15 minutes before closing. Type your submission on a text document (eg. Microsoft Word) and copy and paste it into the abstract text field.
14. Authors must be registrants at the meeting to present and for their abstract to appear in the final program and on the meeting website.
15. Amendments to abstracts after submission is not guaranteed.
16. The submitting author of an abstract will ALWAYS receive email confirmation of receipt of the abstract into the submission site. If you do not receive a confirmation email within 24 hours it may mean the abstract has not been received. In this circumstance, please email anzhnscs.asm@surgeons.org to determine why a confirmation email has not been received.

If there are any difficulties regarding this process please contact the meeting organisers on:

T: +61 3 9249 1158
E: anzhnscs.asm@surgeons.org

Important Note Regarding Disclosure of Potential Conflict of Interest

ANZHNCS policy requires disclosure of all financial relationships between a speaker and the commercial supporter (if applicable) or with the manufacturer of any product or class of products they plan to discuss. This policy is designed to provide the audience with an opportunity to review any affiliations between a speaker and supporting organisations for the purpose of determining the potential presence of bias or influence over content.

This policy is not intended to prevent a speaker with such an affiliation or relationship from participating. Disclosure should be made using a slide at the beginning of your presentation.

Examples of relationships which should be disclosed include but are not limited to:

- any direct financial interest in a company whose interests are in the area(s) covered by the educational material
- investments held by the speaker in a relevant company

- membership on a relevant company's advisory board or similar committee
- current or recent participation in a clinical trial sponsored by a relevant company
- assisting in the design of clinical studies concerning the use of products manufactured by a relevant company
- participating in clinical studies using products produced by a relevant company
- research by the speaker sponsored by a relevant company
- paid speaker by a relevant company
- the speaker holds a patent for a product referred to in the presentation or marketed by a relevant company. To ensure that audiences receive complete information, speakers who have no involvement with industry should inform the audience that they have nothing to disclose, i.e. cannot identify any potential conflict of interest.

Oral Presentations

Electronic PowerPoint presentations must be provided to the speaker support staff at the Adelaide Convention Centre. Presentations are required a minimum of 2 hours prior to the commencement of the assigned session.

Scientific Posters

All posters will be displayed on poster panels during the meeting and will be available for viewing during the breaks. Authors of successful posters should submit their poster to staff at the registration desk upon arrival at the meeting.



DEVICE TECHNOLOGIES

OUR WORLD IS FULL OF EXTRAORDINARY *POSSIBILITIES...*

For over 20 years, Device Technologies has been pioneering possibility in the Australasian healthcare landscape – seeking out and bringing to market, some of the world's most advanced healthcare products.

We are now Australasia's largest independent provider of total healthcare solutions, with a comprehensive range that extends from high quality consumables, to advanced equipment, robotics and fully digital operating theatres.

In partnership with some of the world's most innovative medical companies, our dedicated team of over 800 highly skilled healthcare specialists and support staff, are committed to the provision of superior outcomes for our customers and their patients across the entire healthcare community.

Pioneering Possibility.

📞 1300 DEVICE (338 423) ✉ customers@device.com.au 🌐 www.device.com.au



Grants and Prizes Offered by the ANZHNCs

Grants

ANZHNCs Research Foundation Grant

Amount on offer: \$20,000.00

The ANZHNCs Research Foundation aims to foster valid scientific research aimed at improving the care of people with cancers of the head and neck.

The 2019 Research Grant is open to Australian members. The researcher must agree to present results at the Annual Scientific Meeting (ASM) of the ANZHNCs and to acknowledge the ANZHNCs Research Foundation in any publication resulting from the funded research.

For further details on this grant, including criteria required, please refer to www.anzhncs.org

Applications are due by Friday 31 May 2019.

Developing Nations Visitor Scheme

Amount on offer: \$5,000.00

This grant is awarded to a doctor, allied health or nursing professional (with a relevant higher degree in Oncology or similar) from a developing nation with an interest in head and neck cancer. The applicant is required to attend the ASM, can organise a visit to another Centre and/or is invited to present a paper on life and work in their hospital and head and neck cancer in their society. For further details on this grant, including criteria required, please refer to www.anzhncs.org

Applications are due by Monday 17 June 2019.

Travelling Lectureship Scheme

Amount on offer: \$5,000.00

This grant is awarded to a Medical Officer only, from a developing nation. The applicant is required to present a paper at the ASM, attend the meeting and arrange a visitation to a Head and Neck Centre and become involved in unit activities including MDTs etc. For further details on this grant, including criteria required, please refer to www.anzhncs.org

Applications are due by Monday 17 June 2019.

Allied Health and Nursing Grant Scheme

Amount on offer: \$1,000.00

This grant is awarded to an allied health or nursing professional who successfully submits an abstract for presentation at the ASM and has requested to be considered for the grant (successful applicants whose abstracts are selected by the panel, will be sent an application form to complete). Only one such grant will be awarded at each ASM.

Applications are due by Monday 17 June 2019.

How to apply

For further details on how to apply for grants or prizes, please email the ANZHNCs Secretariat info@anzhncs.org or phone +61 2 9431 8670.

Prizes

Best Overall Oral Presentation and Best Overall Poster Presentation Prizes

Amount \$500.00 each

The above-mentioned prizes are available at the ASM, with the entries being assessed during the meeting and winners announced at the close of the meeting.

Abstract submissions close on Monday 17 June 2019.



Icon
CANCER CENTRE

Care closer to home

With 28 centres spread across metropolitan, outer suburbs and regional areas, Icon believe in providing exceptional cancer care close to home.

Our centres are a combination of day oncology hospitals, radiation oncology centres and comprehensive centres that bring both day oncology and radiation therapy under one roof.

To be part of our iconic conversation follow us at:

    or iconcancercentre.com.au

General Information

Date and Venue

The ANZHNCS ASM 2019 will be held at Adelaide Convention Centre, North Terrace, Adelaide, South Australia from Thursday 19 September to Saturday 21 September 2019. For further information please visit www.adelaideccc.com.au

Registration Desk

The registration desk will be located in the Panorama Ballroom Entry West of the Adelaide Convention Centre.

Opening Hours:

Thursday 19 September 2019: 8:00am – 5:00pm
Friday 20 September 2019: 8:00am – 5:00pm
Saturday 21 September 2019: 8:00am – 12:00noon

Internet Facilities

Wireless internet will be available throughout the meeting. Details will be made available onsite.

Parking

The Adelaide Convention Centre operates two convenient car parks: the Riverbank Car Park and the North Terrace Car Park. The car parks have direct lift access to the Centre's convention floors and exhibition facilities.

Parking Rates

Early Bird: \$16.00
Available 7 days for entry between 5:30am – 9:30am and exit between 2:30pm – 6:30pm.

Casual Rates

0 -1 Hours: \$7.00
1 -2 Hours: \$11.00
2 -3 Hours: \$15.00
3 -4 Hours: \$17.00

An additional \$1.00 will be charged for each additional hour to a maximum of \$29.00 over a 24-hour period.

Intention to Photograph

Please be advised that photographs may be taken during the meeting and reproduced by the meeting organiser.

These photos may be used for the following purposes:

- Projection onsite
- Reporting on the meeting online
- Marketing a future meeting, including online and hard copy publications
- Publishing in RACS publications

If you do not wish to be included in a photograph, please advise the photographer.

Name Badges

Your name badge is essential for entry into scientific sessions. Please collect your meeting materials from the registration desk prior to entering the sessions.

Official Functions

Welcome Reception and Poster Session

Thursday 19 September 2019, 6:00pm – 8:00pm

Venue: Panorama Ballroom, Adelaide Convention Centre

Cost: Included for full registration categories*, bookings essential

**Subject to availability at the time of booking*

Additional tickets: \$75.00 per person

Network with the Academic Faculty, industry and fellow colleagues whilst celebrating the opening of this important meeting.

Meeting Dinner

Friday 20 September 2019, 7:00pm – 10:30pm

Venue: Hickinbotham Hall, National Wine Centre of Australia

Corner of Botanic & Hackney Roads, Adelaide, South Australia

Cost: Included for full registration categories*, bookings essential

**Subject to availability at the time of booking*

Additional tickets: \$160.00 per person

Enjoy a three course dinner and entertainment with colleagues and friends.

Dietary Requirements

Please note that the venue is responsible for all catering at the meeting and ANZHNCS/RACS does not inspect or control food preparation areas or attempt to monitor ingredients used. You should contact the venue directly for all special dietary requirements during the event, irrespective of whether details have been provided to ANZHNCS/RACS. If ANZHNCS/RACS requests information about your dietary requirements for a specific event ANZHNCS/RACS will endeavour to forward the information provided to the venue (time permitting). ANZHNCS/RACS will not retain information provided for future events, so you must verify your requirements for each event. Even if information is requested or provided, ANZHNCS/RACS takes no responsibility for ensuring that the venue acknowledges your dietary requirements or that these requirements can be met. In all cases you must verify for yourself that your dietary requirements have been met and ANZHNCS/RACS refutes any and all liability for any failure to adequately provide your special dietary requirements or any consequential damage resulting from such failure.



Registration Information

Full registration includes:

- Access to all scientific sessions
- Meeting materials
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program
- Welcome Reception (Thursday 19 September 2019)*
- Meeting Dinner (Friday 20 September 2019)*

If you would like to attend any of the above activities, please indicate your attendance on the ANZHNCS ASM registration form.

**The Welcome Reception and Meeting Dinner is not included in day registration categories. Tickets must be purchased separately.*

One day registration includes:

- Access to all scientific sessions (as applicable)
- Meeting materials
- Access to the industry exhibition
- Morning and afternoon tea refreshments in accordance with the program
- Lunch in accordance with the program

Concessional Registration

Concessional registration is available to nurses, allied health professionals, trainees and medical students.

Industry Representatives Registration

Registration is open to representatives from companies participating in the industry exhibition only. Registrations from representatives of non-participating companies will not be accepted.

Cancellation

Cancellations must be notified in writing to: anzhnscs.asm@surgeons.org

A cancellation fee of 20% of the appropriate registration fee will be charged for cancellations received prior to Monday 12 August 2019. Please note there will be no refunds after Monday 12 August 2019.

Early registration closes: Monday 12 August 2019

Dress

Scientific Sessions: Business attire or smart casual
Welcome Reception: Business attire or smart casual
Meeting Dinner: Lounge suit/cocktail dress

Continuing Medical Education (CME)/Continuing Professional Development (CPD) Points

Please refer to the meeting website for updates regarding eligibility for CME/CPD points.

Certificate of Attendance

A certificate of attendance will be circulated electronically at the conclusion of the meeting.

KLS martin
GROUP



Individual Patient Solutions



Delegate Registration Form

Register online at www.anzhncs.org

Title: _____ First Name: _____ Surname: _____

Preferred name for name badge: _____

Organisation / Institution for name badge: _____

RACS ID (if applicable): _____ (Provide your RACS ID for automatic allocation of CPD points.)

Please indicate your profession: ☐ Surgeon (please specify type) _____

☐ Oncologist (please specify type) _____ ☐ Trainee (please specify type) _____

☐ Speech Pathologist ☐ Nurse ☐ Dietitian ☐ Psychologist ☐ Medical Student ☐ Other (please specify) _____

Address: _____

Town/City: _____ State: _____ Postcode/Zipcode: _____ Country: _____

Tel + IDD (Work): _____ Tel + IDD (Home): _____ Fax + IDD: _____

Mobile: _____ Email: _____

(All meeting correspondence will be issued by email).

☐ Please tick this box if you do not want your Name, Organisation/Institution, State and/or Country circulated to delegates or the industry

Full Registration includes: all scientific sessions, final program, lunch, morning and afternoon tea, entry to the industry exhibition, welcome reception and meeting dinner (limited – subject to availability at time of registration).

FULL REGISTRATION Thursday 19 – Saturday 21 September 2019 <i>All costs in Australian Dollars and includes GST.</i>	Early Fee Per Person (ends 12 Aug 2019)	Standard Fee Per Person	Subtotal	Must tick to register for Welcome Reception (included in full registration)	Must tick to register for Meeting Dinner (included in full registration)
ANZHNCS Full Member (Medical Specialist)*	\$1,100.00	\$1,300.00	\$	<input type="checkbox"/>	<input type="checkbox"/>
ANZHNCS Full Member (Other Health Professional)*	\$660.00	\$770.00	\$		
<i>*Member rates only apply to members of the Australian and New Zealand Head & Neck Cancer Society.</i>					
Nurse/Allied Health Professional	\$770.00	\$880.00	\$		
Trainee/Medical Student	\$660.00	\$770.00	\$		
Non Member Specialist Fee	\$1,300.00	\$1,550.00	\$		
Full Registration Subtotal			\$		

Day Only Registration includes: all scientific sessions, final program, lunch, morning and afternoon tea (as applicable) and entry to the industry exhibition.

DAY ONLY REGISTRATION <i>All costs in Australian Dollars and includes GST.</i>	Early Fee Per Person (ends 12 Aug 2019)	Standard Fee Per Person	No. of Days	Subtotal	Tick day/s attending:		
					Thursday 19 September	Friday 20 September	Saturday 21 September
ANZHNCS Full Member (Medical Specialist)*	\$550.00	\$650.00		\$	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
ANZHNCS Full Member (Other Health Professional)*	\$330.00	\$440.00		\$			
<i>*Member rates only apply to members of the Australian and New Zealand Head & Neck Cancer Society.</i>							
Nurse/Allied Health Professional	\$385.00	\$495.00		\$			
Trainee/Medical Student	\$330.00	\$440.00		\$			
Non Member Specialist Fee	\$660.00	\$800.00		\$			
One Day Registration Subtotal				\$			

ADDITIONAL TICKETS – OFFICIAL FUNCTIONS <i>All costs in Australian Dollars and includes GST.</i>	Fee Per Person	No. of Persons	Subtotal
Welcome Reception – Thursday 19 September 2019	\$75.00		\$
Meeting Dinner – Friday 20 September 2019	\$160.00		\$
Additional Tickets – Official Functions Subtotal			\$

Return to:

ANZHNCS Annual Scientific Meeting 2019

Conferences and Events Management
Royal Australasian College of Surgeons
250 - 290 Spring Street
East Melbourne VIC 3002
AUSTRALIA
T: +61 3 9249 1158
F: +61 3 9276 7431
E: anzhnscs.asm@surgeons.org

Cancellations must be notified in writing to:
anzhnscs.asm@surgeons.org

A cancellation fee of 20% of the appropriate registration fee will be charged for cancellations received prior to Monday 12 August 2019. Please note there will be no refunds after Monday 12 August 2019.

Total of Fees	
Full Registration Fee	\$
Day Only Registration Fee	\$
Additional Tickets – Official Functions	\$
TOTAL PAYABLE	\$

Royal Australasian College of Surgeons ABN 29 004 167 766 Privacy Policy details can be viewed on the RACS website at www.surgeons.org/disclaimerprivacy/

PAYMENT OPTIONS (Please tick)

☐ **Cheque** – A cheque made payable to the Royal Australasian College of Surgeons must accompany this form.

☐ **Credit Card/PayPal** – Payment instructions will be emailed to you upon processing of your registration.



Accommodation Options

Please complete booking via: <https://corporateblue.eventsair.com/anzhnscs-adelaide-2019/accommodation/>.
For further enquiries please contact Corporate Blue at: anzhnscs@corporateblue.com.au or +61 3 9578 6555.
A reservation email will be sent after accommodation has been confirmed.

**Accommodation is subject to availability at time of booking.*

Oaks Embassy

★★★★★



96 North Terrace, Adelaide

T: +61 8 8124 9900

E: embassy@theoaksgroup.com.au

www.oaks.com.au

1 minute walk to the Adelaide Convention Centre

Oaks Embassy is a contemporary apartment building offering spacious fully self-contained apartments with full kitchen and laundry facilities. Guests will enjoy the hotel's luxurious facilities which include an indoor heated lap pool, sauna and gymnasium.

Check in: 2:00pm
Check out: 10:00am

Rate:

Two Bedroom Apartment

\$259.00 per room per night including GST.

Rate excludes breakfast and includes GST and Wi-Fi.

Stamford Plaza Adelaide

★★★★★



150 North Terrace, Adelaide

T: +61 8 8376 1222

www.stamford.com.au/spa

6 minute walk to the Adelaide Convention Centre

Stamford Plaza Adelaide hotel offers elegantly furnished, spacious guest rooms with views of the Adelaide historic parklands, Adelaide Oval or the city.

Check in: 2:00pm
Check out: 11:00am

Rate:

Park View Room

\$199.00 per room per night including GST.

Rate excludes breakfast and includes GST and Wi-Fi.

The Playford, MGallery by Sofitel

★★★★★



120 North Terrace, Adelaide

T: +61 8 8213 8888

www.theplayford.com.au/

1 minute walk to the Adelaide Convention Centre

The Playford, MGallery by Sofitel, is a boutique hotel in the heart of Adelaide on the vibrant North Terrace.

Guest facilities include a fully equipped Health Club with indoor heated pool, spa and sauna, business centre and guest laundry. The Playford is ideally situated to the Adelaide Convention Centre, central business district, shopping and restaurant district all within walking distance.

Check in: 2:00pm
Check out: 11:00am

Rate:

Standard Guest Room

\$193.00 per room per night includes GST.

Rate excludes breakfast and includes GST and Wi-Fi.

Adelaide Highlights

Below are some optional activities to enjoy pre and post meeting.

For more ideas and destination information visit: www.southaustralia.com

Adelaide City Highlights



Your guide will introduce you to this delightful city, which is surrounded by parklands with a blend of historic buildings, wide streets, cafes and restaurants. Drive past Adelaide's cultural precinct - North Terrace, the National Wine Centre, Adelaide Botanic Gardens and the beautiful Botanic Park, home to the Bicentennial Conservatory and the Adelaide Zoo. Continue through historic North Adelaide, where you'll see tree-lined streets, mansions and historic buildings. Stop and visit the iconic St Peters Cathedral or the newly developed Adelaide Oval then travel through the city's east on the way to Haigh's Chocolates for a factory tour and tastings of this famous South Australian chocolate. Return to the city via the South Park lands, West Terrace and North Terrace.

Book through the Adelaide Convention Bureau:

<http://www.adelaideconvention.com.au/tours/sealink-adelaide-city-highlights-tour/>

Barossa Food and Wine Experience



Travel in a small coach and enjoy a food and wine journey to South Australia's premium wine region, the Barossa. Take time to sample some of the Barossa's finest wines and gourmet food that makes this wine region so special. On this tour visit five cellar doors including the world-famous Wolf Blass Visitor Centre, enjoy a Barossa gourmet lunch and wine tastings at this spectacular cellar door facility.

Book through the Adelaide Convention Bureau:

<http://www.adelaideconvention.com.au/tours/sealink-barossa-food-wine/>

Adelaide Central Market



The Adelaide Central Market has been a thriving hub of food and culture for over 150 years. With over 70 traders under one roof, the market is one of the largest undercover fresh produce markets in the southern hemisphere, buzzing with life and colour all year round. This market is where the locals go for their fresh food, great cafes and restaurants.

www.adelaidecentralmarket.com.au

Glenelg Beach



Glenelg Beach is Adelaide's most popular city beach, offering a buzzing vibe and great atmosphere for all to enjoy. Renowned for its wide beach, stunning sunsets, rich heritage charming hotels, bustling shops and sidewalk cafes.

<https://southaustralia.com/products/adelaide/attraction/glenelg-beach>



Adelaide Zoo



See the only Giant Pandas in Australia at the Adelaide Zoo. Just a short 15 minute walk from major CBD hotels; visit these gorgeous creatures in their state-of-the-art purpose-built enclosure. Or as an alternative, get up close and personal with them by taking one of the exhilarating behind the scenes tours (additional fees apply).

www.adelaidezoo.com.au

Haigh's Chocolate Factory



One of the most popular free tours you can do in Adelaide is the Haigh's Chocolate Factory Tour. The tours run for 20 minutes and guests can also sample some of the famous chocolates. Bookings are recommended.

<https://www.haighschocolates.com.au/tours>

Kangaroo Island



Kangaroo Island is one of the world's great nature-based destinations, which also offers boutique local cuisine and beverages. Be greeted by Australian sea lions basking on unspoiled white beaches, koalas dozing in lofty eucalyptus trees and pelicans gliding across shimmering lagoons. Enjoy hikes through bushland, towering gum trees and along the rugged coastline. Visiting foodies will be spoilt for choice with freshly-caught fish, oysters, cheese and honey. Discover a rich history, thriving arts community and exciting wilderness retreats on Kangaroo Island.

<https://www.tourkangarooisland.com.au/>

ANZHNCs ASM 2019

Australian and New Zealand Head & Neck Cancer Society
21st Annual Scientific Meeting

19 – 21 September 2019
Adelaide Convention Centre
ADELAIDE, SOUTH AUSTRALIA



Meeting Organisers

Conferences & Events Management
Royal Australasian College of Surgeons
College of Surgeons Gardens
250 – 290 Spring Street
East Melbourne VIC 3002
Australia

T: +61 3 9249 1158
F: +61 3 9276 7431
E: anzhnscs.asm@surgeons.org

www.anzhnscs.org